Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04484259 · ClinicalTrials.gov registry record · Phase 4
Ticagrelor With and Without Aspirin in Patients With Diabetes Mellitus
A Phase 4 study of Diabetes Mellitus, Type 2 and Coronary Artery Disease, sponsored by University of Florida.
- Completed
- Registry status
- Phase 4
- Development phase
- 105
- Enrollment target
- 1
- Study location
NCT04484259 is a Phase 4 study of Diabetes Mellitus, Type 2 and Coronary Artery Disease that has completed, run by University of Florida. The registered enrollment target is 105 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04484259, a Phase 4 study of Diabetes Mellitus, Type 2 and Coronary Artery Disease, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 105 participants
- Enrollment target
- 1
- Study location
Study Summary
Recent studies have shown that withdrawing aspirin and maintaining P2Y12 inhibitor monotherapy for up to 12 months post-PCI, after a brief period of DAPT, reduces bleeding without increasing ischemic harm. Such effects have shown to of particular benefit in patients with diabetes mellitus (DM). However, if an aspirin-free approach can be considered after this time frame is a matter of debate. The aim of this study is to assess the PD effects of ticagrelor 60 mg with and without aspirin therapy in CAD patients and to compare this with a standard DAPT regimen of aspirin plus clopidogrel.
Conditions Studied
Interventions
- DRUG Ticagrelor monotherapy
- DRUG Ticagrelor plus aspirin
- DRUG Clopidogrel with aspirin
Study Locations (1)
Florida
- University of Florida - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2021-03-31 |
| Est. Completion | 2024-06-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04484259
The ClinicalTrials.gov registry entry for NCT04484259 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (98% lower). The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 3 interventions - of which Ticagrelor monotherapy is the first listed.
NCT04484259 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT04484259 about?
NCT04484259 is a clinical study titled "Ticagrelor With and Without Aspirin in Patients With Diabetes Mellitus". Recent studies have shown that withdrawing aspirin and maintaining P2Y12 inhibitor monotherapy for up to 12 months post-PCI, after a brief period of DAPT, reduces bleeding without increasing ischemic harm. Such effects have shown to of particular benefit in patients with diabetes mellitus (DM). Howe...
What is the current status of trial NCT04484259?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 105 participants. The study started on 2021-03-31. Estimated completion is 2024-06-15.
What conditions does trial NCT04484259 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Coronary Artery Disease.
What interventions are being tested in trial NCT04484259?
The interventions under investigation include: Ticagrelor monotherapy (DRUG), Ticagrelor plus aspirin (DRUG), Clopidogrel with aspirin (DRUG).
Who is sponsoring clinical trial NCT04484259?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04484259 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes
RECRUITING · Phase 4
-
Knee Osteoarthritis Treatment With Zilretta vs. Kenalog in the Context of Type II Diabetes
RECRUITING · Phase 4
-
Effect of Continuing Versus Holding Metformin During Hospitalizations.
RECRUITING · Phase 4
-
Surgical or Medical Treatment
ACTIVE NOT RECRUITING · Phase 4
-
Afrezza® Dosing Optimization Study
COMPLETED · Phase 4
-
Effect of Thiazolidinedione Treatment Vascular Risk Markers
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.